PMID- 29849470
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1179-156X (Print)
IS  - 1179-156X (Electronic)
IS  - 1179-156X (Linking)
VI  - 10
DP  - 2018
TI  - Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the 
      treatment of knee osteoarthritis.
PG  - 43-54
LID - 10.2147/OARRR.S162127 [doi]
AB  - BACKGROUND: Pain and limitations in joint mobility associated with knee 
      osteoarthritis (OA) are clinically challenging to manage, and advanced 
      progression of disease can often lead to total knee arthroplasty. Intra-articular 
      injection of hyaluronic acid (HA), also referred to as viscosupplementation, is a 
      non-surgical treatment approach for OA, the effectiveness of which may depend on 
      the HA composition, and the length of time over which it resides in the joint. 
      One of the available options for such therapies includes NASHA (Durolane HA), a 
      non-animal, biofermentation-derived product, which is manufactured using a 
      process that stabilizes the HA molecules to slow down their rate of degradation 
      and produce a unique formulation with a terminal half-life of ~1 month. The 
      objectives of the current review were to assess, in patients with OA of the knee, 
      the efficacy and safety of intra-articular treatment with NASHA relative to 
      control (saline) injections, other HA products, and other injectables 
      (corticosteroids, platelet-rich plasma, mesenchymal stem cells). METHODS: This 
      systematic evidence review examines patient outcomes following NASHA treatment as 
      described in published data from studies conducted in subjects with knee OA. A 
      Preferred Reporting Items for Systematic Reviews and Meta-analyses-compliant 
      literature search strategy yielded 11 eligible clinical studies with a variety of 
      comparator arms. Outcomes assessed at various time points following 
      intra-articular treatment included measures of pain, function, quality of life, 
      and incidence of treatment-related adverse events (AEs). RESULTS: The available 
      evidence reported for the clinical studies assessed demonstrates sustained and 
      effective relief of knee OA symptoms following a single injection of NASHA. In 
      addition, an excellent biocompatibility profile is observed for NASHA as an 
      intra-articular therapy for OA, as reflected by the low rate of AEs associated 
      with treatment. CONCLUSION: Treatment with NASHA is an effective and safe 
      single-injection procedure, which can be beneficial in the clinical management of 
      knee OA.
FAU - Leighton, Ross
AU  - Leighton R
AD  - Department of Surgery, Dalhousie University, Halifax, NS, Canada.
FAU - Fitzpatrick, Jane
AU  - Fitzpatrick J
AD  - Sports Medicine Professionals Pty Ltd, Richmond, VIC, Australia.
AD  - University of Western Australia, Perth, WA, Australia.
FAU - Smith, Helen
AU  - Smith H
AD  - Bioventus LLC, Durham, NC, USA.
FAU - Crandall, Daniela
AU  - Crandall D
AD  - Bioventus LLC, Durham, NC, USA.
FAU - Flannery, Carl R
AU  - Flannery CR
AD  - Bioventus LLC, Durham, NC, USA.
FAU - Conrozier, Thierry
AU  - Conrozier T
AD  - Department of Rheumatology, Hospital Nord Franche-Comte, Belfort, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180521
PL  - New Zealand
TA  - Open Access Rheumatol
JT  - Open access rheumatology : research and reviews
JID - 101688698
PMC - PMC5967379
OTO - NOTNLM
OT  - Durolane
OT  - NASHA
OT  - clinical outcomes
OT  - hyaluronic acid
OT  - intra-articular
OT  - osteoarthritis
OT  - residence time
OT  - symptomatic relief
OT  - viscosupplementation
COIS- Disclosure HS, DC, and CRF are employees and RL, JF, and TC are consultants of 
      Bioventus LLC. The authors report no other conflicts of interest in this work.
EDAT- 2018/06/01 06:00
MHDA- 2018/06/01 06:01
PMCR- 2018/05/21
CRDT- 2018/06/01 06:00
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/01 06:01 [medline]
PHST- 2018/05/21 00:00 [pmc-release]
AID - oarrr-10-043 [pii]
AID - 10.2147/OARRR.S162127 [doi]
PST - epublish
SO  - Open Access Rheumatol. 2018 May 21;10:43-54. doi: 10.2147/OARRR.S162127. 
      eCollection 2018.